Ainos signs VELDONA license deal with BioPhoenix worth up to $10 million

PUBT · 1d ago
Ainos signs VELDONA license deal with BioPhoenix worth up to $10 million
  • Ainos signed a VELDONA license deal with BioPhoenix, setting a conditional collaboration framework valued at up to USD 10 million.
  • BioPhoenix secured exclusive worldwide rights for Sjögren's disease and thrombocytopenia, covering development, manufacturing, and commercialization.
  • BioPhoenix will fund and run assigned clinical and regulatory work, shifting late-stage development costs away from Ainos.
  • Framework includes an upfront license fee, potential payments for up to 15 additional indications, and a one-time fee on BioPhoenix’s first sublicense.
  • Ainos will receive 25% of applicable net sublicensing revenue, separate from license fees and any product supply revenue.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ainos Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609240800ACCESSWRNAPR_____1226495) on September 24, 2026, and is solely responsible for the information contained therein.